Chronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, Minnesota.
Division of Nephrology, Hennepin Healthcare, Minneapolis, Minnesota.
J Am Soc Nephrol. 2021 Nov;32(11):2948-2957. doi: 10.1681/ASN.2021040579. Epub 2021 Sep 17.
The COVID-19 pandemic caused major disruptions to care for patients with advanced CKD.
We investigated the incidence of documented ESKD, ESKD treatment modalities, changes in eGFR at dialysis initiation, and use of incident central venous catheters (CVCs) by epidemiologic week during the first half of 2020 compared with 2017-2019 historical trends, using Centers for Medicare and Medicaid Services data. We used Poisson and logistic regression for analyses of incidence and binary outcomes, respectively.
Incidence of documented ESKD dropped dramatically in 2020 compared with the expected incidence, particularly during epidemiologic weeks 15-18 (April, incidence rate ratio [IRR], 0.75; 95% CI, 0.73 to 0.78). The decrease was most pronounced for individuals aged ≥75 years (IRR, 0.69; 95% CI, 0.66 to 0.73). Pre-emptive kidney transplantation decreased markedly during weeks 15-18 (IRR, 0.56; 95% CI, 0.46 to 0.67). Mean eGFR at dialysis initiation decreased by 0.33 ml/min per 1.73 m in weeks 19-22; non-Hispanic Black patients exhibited the largest decrease, at 0.61 ml/min per 1.73 m. The odds of initiating dialysis with eGFR <10 ml/min per 1.73 m were highest during weeks 19-22 (May, OR, 1.14; 95% CI, 1.05 to 1.17), corresponding to an absolute increase of 2.9%. The odds of initiating peritoneal dialysis (versus hemodialysis) were 24% higher (OR, 1.24; 95% CI, 1.14 to 1.34) in weeks 11-14, an absolute increase of 2.3%. Initiation with a CVC increased by 3.3% (OR, 1.30; 95% CI, 1.20 to 1.41).
During the first wave of the COVID-19 pandemic, the number of patients starting treatment for ESKD fell to a level not observed since 2011. Changes in documented ESKD incidence and other aspects of ESKD-related care may reflect differential access to care early in the pandemic.
COVID-19 大流行严重扰乱了晚期慢性肾脏病患者的治疗。
我们利用医疗保险和医疗补助服务中心的数据,比较了 2020 年上半年与 2017-2019 年历史趋势的每个流行病学周记录的终末期肾病(ESKD)、ESKD 治疗方式、透析开始时 eGFR 的变化,以及新置入中心静脉导管(CVC)的情况。我们分别使用泊松和逻辑回归分析发病率和二项结果。
与预期发病率相比,2020 年记录的 ESKD 发病率显著下降,尤其是在第 15-18 个流行病学周(4 月,发病率比[IRR],0.75;95%CI,0.73-0.78)。75 岁及以上人群降幅最为明显(IRR,0.69;95%CI,0.66-0.73)。第 15-18 个流行病学周期间,预防性肾脏移植明显减少(IRR,0.56;95%CI,0.46-0.67)。第 19-22 个流行病学周透析开始时 eGFR 平均下降 0.33ml/min/1.73m;非西班牙裔黑人患者的降幅最大,为 0.61ml/min/1.73m。第 19-22 个流行病学周(5 月)eGFR<10ml/min/1.73m 开始透析的几率最高(OR,1.14;95%CI,1.05-1.17),绝对增加 2.9%。第 11-14 个流行病学周腹膜透析(vs 血液透析)的起始几率高 24%(OR,1.24;95%CI,1.14-1.34),绝对增加 2.3%。CVC 使用率增加 3.3%(OR,1.30;95%CI,1.20-1.41)。
在 COVID-19 大流行的第一波期间,开始接受 ESKD 治疗的患者人数下降至 2011 年以来未见的水平。记录的 ESKD 发病率和其他方面的 ESKD 相关治疗的变化可能反映了大流行早期护理机会的差异。